ARS Pharmaceuticals Inc. (SPRY)
12.49
-0.14 (-1.11%)
At close: Mar 28, 2025, 3:59 PM
12.50
0.04%
After-hours: Mar 28, 2025, 05:03 PM EDT
Company Description
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites.
Its product includes Neffy, a low-dose intranasal epinephrine nasal spray.
The company was incorporated in 2015 and is based in San Diego, California.
ARS Pharmaceuticals Inc.

Country | United States |
IPO Date | Dec 4, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 155 |
CEO | Richard Lowenthal M.B.A., M.S., MSMSEL |
Contact Details
Address: 3525 Del Mar Heights Road San Diego, California United States | |
Website | https://ars-pharma.com |
Stock Details
Ticker Symbol | SPRY |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001671858 |
CUSIP Number | 82835W108 |
ISIN Number | US82835W1080 |
Employer ID | 81-1489190 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Richard Lowenthal M.B.A., M.S., MSMSEL | Co-Founder, President, Chief Executive Officer & Director |
Alexander A. Fitzpatrick Esq. | Chief Legal Officer & Secretary |
Kathleen D. Scott CPA | Chief Financial Officer |
Brian T. Dorsey M.S. | Chief Operations Officer |
Daniel Relovsky | Senior Vice President of Marketing |
Dr. Robert Bell Ph.D. | Co-Founder & Chief Science Officer |
Dr. Sarina Tanimoto M.B.A., M.D. | Co-Founder & Chief Medical Officer |
Eric Karas | Chief Commercial Officer |
Harris Kaplan M.B.A. | Executive Vice President of Commercial Strategy |
Justin Chakma | Chief Business Officer & Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 24, 2025 | SCHEDULE 13D/A | [Amend] Filing |
Mar 21, 2025 | 4 | Filing |
Mar 20, 2025 | S-8 | Filing |
Mar 20, 2025 | 10-K | Annual Report |
Mar 20, 2025 | 8-K | Current Report |
Mar 07, 2025 | 4 | Filing |
Mar 05, 2025 | 8-K | Current Report |
Feb 04, 2025 | 4 | Filing |
Jan 31, 2025 | S-3ASR | Automatic shelf registration statement of securiti... |
Jan 13, 2025 | 8-K | Current Report |